Gilead says its twice-yearly shot cut HIV infections by 96% in trial
Gilead‘s twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday. The positive phase-three…
This ETF is trying to satisfy appetites for weight loss stocks
Tema ETFs has been capitalizing on the risk appetite for weight loss stocks. It is behind the GLP-1, Obesity &…
Trump claims credit for Biden’s insulin price cap
Former President Donald Trump on Saturday recognized that the price of insulin is lower under President Joe Biden, but he…
DOJ settles CityMD Covid fraud allegations for $12 million
Walgreens-backed CityMD will pay $12.04 million to settle Covid fraud allegations brought by the Department of Justice, the department announced…
Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.
The U.S. Senate has launched an investigation into the high price of Novo Nordisk‘s popular weight loss and diabetes drugs…
Fed must get ‘more aggressive’ with rate cuts due to weakening jobs market, Canaccord’s chief market strategist says
The Federal Reserve may have new incentives in the second quarter to cut rates deeper this year. Canaccord Genuity’s Tony…
Falling fertility rates pose major challenges for the global economy, report finds
Falling fertility rates are set to spark a transformational demographic shift over the next 25 years, with major implications for…
Megacap tech stocks dominate many ESG funds. Here’s why
The top holdings of many ESG funds may be surprisingly familiar. While these strategies consider a company’s environmental, social and…
Nvidia rally is fueling FOMO in the overall market, Evercore’s Julian Emanuel warns
Evercore ISI’s Julian Emanuel thinks Nvidia’s monster rally is fueling a fear of missing out in the market. He finds…
